Knight Therapeutics Inc. - 28 Jul 2023 Form 4 Insider Report for 60 DEGREES PHARMACEUTICALS, INC. (SXTP)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
03 Apr 2024, 18:00:43 UTC
Prior SEC filing
18 Dec 2023
Next SEC filing
22 Oct 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
KNIGHT THERAPEUTICS INC. By: /s/ Samira Sakhia Name: Samira Sakhia Title: President and Chief Executive Officer
Filing notes and source

Key filing fact

Knight Therapeutics Inc. filed Form 4 for 60 DEGREES PHARMACEUTICALS, INC. (SXTP) on 03 Apr 2024.

Key facts

  • This page summarizes Knight Therapeutics Inc.'s Form 4 filing for 60 DEGREES PHARMACEUTICALS, INC. (SXTP).
  • 2 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 03 Apr 2024, 18:00.

Change

  • Previous filing in this sequence was filed on 18 Dec 2023.
  • Current net transaction value: +$216,182.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SXTP transaction

Common Stock, $0.0001 par value per share ("Common Shares")

Conversion of derivative security

Transaction value
$216,182
Shares
+45,560
Change %
+4.1%
Price
$4.74
Shares after
1,153,897
Date
28 Jul 2023
Ownership
By Knight Therapeutics International S.A.
Footnotes
F1, F2, F3, F4
SXTP transaction

Series A Non-Voting Convertible Preferred Stock

Conversion of derivative security

Transaction value
$0
Shares
-2,162
Change %
-2.7%
Price
$0.000000
Shares after
78,803
Date
28 Jul 2023
Ownership
By Knight Therapeutics International S.A.
Footnotes
F1, F2, F3, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Knight Therapeutics Inc. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

On July 28, 2023, 60 Degrees Pharmaceuticals, Inc. (the "Issuer"), at its sole discretion, converted 2,162 shares of Series A Non-Voting Convertible Preferred Stock (the "Preferred Stock") held by Knight Therapeutics International S.A., an Uruguayan corporation ("Knight Subsidiary") into 45,560 Common Shares, at a conversion price equal to the 10 day volume weighted average price of the Common Shares immediately prior to the conversion. The Preferred Stock has a floating conversion price. Only the Issuer can cause shares of Preferred Stock to be converted into Common Shares. The conversion price of the Preferred Stock is determined in respect of the shares of Preferred Stock that are actually converted into Common Shares by the Issuer at the time of such conversion. The timing of conversion of any shares of Preferred Stock occurrence is outside of the control of the holder of the Preferred Stock.

Footnote F2

After giving effect to the transaction reported on this Form 4, Knight Subsidiary directly beneficially owns 1,153,897 Common Shares, corresponding to 9.97% ownership interest based on 11,570,578 Common Shares issued and outstanding as of April 1, 2024, and 78,803 Preferred Stock convertible only at the sole discretion of the Issuer. Knight Therapeutics Inc., a Canadian corporation ("Knight Parent" and collectively with Knight Subsidiary, the "Reporting Persons") indirectly beneficially owns 1,153,897 Common Shares, and 78,803 Preferred Stock convertible only at the sole discretion of the Issuer.

Footnote F3

None of the Reporting Persons can cause the Preferred Stock to be converted into Common Shares, and the Reporting Persons have no control over the occurrence or timing of a conversion of the Preferred Stock by the Issuer into Common Shares. The shares of Preferred Stock are not "derivative securities." The Reporting Persons do not beneficially own any of the Common Shares underlying the Preferred Stock until such time as the Issuer actually converts shares of Preferred Stock held by the Reporting Persons into Common Shares.

Footnote F4

Knight Parent is the sole owner of Knight Subsidiary and, as a result, may be deemed the beneficial owner for purposes of Securities Exchange Act of 1934 (the "Act") of any securities of the Issuer beneficially owned by Knight Subsidiary. Knight Parent disclaims beneficial ownership over all of the Common Shares beneficially owned by Knight Subsidiary, other than for the purpose of determining obligations under the Act, and the filing of this Form 4 shall not be deemed an admission that Knight Parent is the beneficial owner of such securities for any other purpose.

SEC remarks

As of March 31, 2024, the Reporting Persons are no longer beneficial owners of more than 10% of the Issuer's securities and, as such, this filing represents an exit filing for each Reporting Person. This Form 4 is being jointly filed by Knight Parent and Knight Subsidiary. Exhibit 99.1 (Joint Filer Information) incorporated herein by reference.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .